食品科学 ›› 2026, Vol. 47 ›› Issue (16): 399-407.doi: 10.7506/spkx1002-6630-20260217-124

• 专题论述 • 上一篇    下一篇

缓解高尿酸血症益生菌菌株特异性筛选策略与作用机制研究进展

周毅,夏永军,宋馨,熊智强,王光强,谢凡,艾连中,杨昳津   

  1. (1.上海理工大学健康科学与工程学院,上海 200093;2.上海交通大学农业与生物学院,上海 200240)
  • 出版日期:2026-08-25 发布日期:2026-09-03
  • 基金资助:
    上海东方英才拔尖计划项目(T2024105);2025年度上海市关键技术研发计划“合成生物学”项目(25HC2830500); 国家乳业技术创新中心关键技术攻关项目(19DZ2281100)

Research Progress on Strain-Specific Screening Strategies and Mechanisms of Action of Probiotics in Alleviating Hyperuricemia

ZHOU Yi, XIA Yongjun, SONG Xin, XIONG Zhiqiang, WANG Guangqiang, XIE Fan, AI Lianzhong, YANG Yijin   

  1. (1. School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China;2. School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai 200240, China)
  • Online:2026-08-25 Published:2026-09-03

摘要: 益生菌通过调节肠道微生态干预高尿酸血症(hyperuricemia,HUA)展现出巨大潜力,但临床研究中疗效的不一致性表明其降尿酸功能高度依赖于菌株特异性,而非简单的普适性。本文聚焦于益生菌干预HUA的菌株筛选、作用机制与临床转化。基于肠-肾轴在尿酸稳态调节中的核心作用,分析现有体外筛选方法中单一降解指标的局限,提出整合定植能力与代谢产物生成能力的多维筛选策略。在此基础上,深入探讨特定菌株通过抑制肝脏黄嘌呤氧化酶、调节肾脏尿酸转运体以及利用短链脂肪酸重塑肠道屏障的差异作用机制。此外,针对目前临床转化的瓶颈,从个体疗效差异、菌株稳定性及安全性评价等方面进行分析,旨在为未来开发基于菌株功能特性的精准干预方案提供理论参考。

关键词: 高尿酸血症;益生菌;菌株特异性;尿酸代谢;肠-肾轴

Abstract: Probiotics have demonstrated significant potential in modulating intestinal microecology to intervene in hyperuricemia (HUA); however, the variability in therapeutic outcomes observed in clinical studies suggests that their urate-lowering efficacy is highly strain-specific rather than a universal trait. This review focuses on the strain selection criteria, the mechanisms of action, and the clinical translation of probiotic interventions for HUA. Grounded in the pivotal role of the gut-kidney axis in maintaining uric acid homeostasis, this article critiques the limitations of existing in vitro screening methods that rely on single degradation metrics. Consequently, it proposes a multidimensional screening strategy that integrates colonization capacity with metabolic profiles. Furthermore, the review elucidates the differential mechanisms by which specific strains inhibit hepatic xanthine oxidase, modulate renal urate transporters, and fortify the intestinal barrier via short-chain fatty acid production. Finally, this article discusses current bottlenecks in clinical translation from three aspects: inter-individual variability in therapeutic response, strain stability, and safety assessment, aiming to provide a theoretical basis for the development of precision interventions based on the functional characteristics of probiotic strains for HUA.

Key words: hyperuricemia; probiotics; strain-specific; uric acid metabolism; gut-kidney axis

中图分类号: